OpenAlex
PricingAboutJobs
Log inGet started
Work

Modeling effects of SGLT ‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

HTML

Year: 2014
Type: article
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12261
Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H. L. Grossman, M. Cohen
Institutions: AstraZeneca (United States), Bristol-Myers Squibb (United States)
Language: English

Topic: Diabetes Treatment and Management
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: dapagliflozin, SGLT2 inhibitors, type 2 diabetes, cardiovascular outcomes, microvascular complications, computer simulation, metformin, sulfonylureas, thiazolidinediones, myocardial infarction, stroke, end-stage renal disease, foot amputation, diabetic retinopathy, all-cause mortality
SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, AstraZeneca
OpenAlex ID: W1503352903
FWCI: 8.909
Cites: 31
Cited by: 107
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security